首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity
【24h】

Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity

机译:DNA旋转酶B(GyrB)和拓扑异构酶IV(PARE)的吡咯哒嘧啶抑制剂。 第一部分:结构引导和优化双靶向剂,具有效率,广谱酶活性

获取原文
获取原文并翻译 | 示例
           

摘要

The bacterial topoisomerases DNA gyrase (GyrB) and topoisomerase IV (ParE) are essential enzymes that control the topological state of DNA during replication. The high degree of conservation in the ATP-binding pockets of these enzymes make them appealing targets for broad-spectrum inhibitor development. A pyrrolopyrimidine scaffold was identified from a pharmacophore-based fragment screen with optimization potential. Structural characterization of inhibitor complexes conducted using selected GyrB/ParE orthologs aided in the identification of important steric, dynamic and compositional differences in the ATP-binding pockets of the targets, enabling the design of highly potent pyrrolopyrimidine inhibitors with broad enzymatic spectrum and dual targeting activity. ? 2012 Elsevier Ltd. All rights reserved.
机译:细菌拓扑异构酶DNA乙酶(GyrB)和拓扑异构酶IV(Pare)是在复制期间控制DNA拓扑状态的基本酶。 这些酶的ATP结合袋中的高守恒度使得它们对广谱抑制剂发育的吸引力靶向。 通过优化潜力从基于药疗法的片段筛网中鉴定吡咯基嘧啶支架。 在靶向靶标的鉴定中使用选定的陀螺/ PARE直肠进行的抑制剂复合物的结构表征在靶标的重要空间,动态和组成差异中,使具有广泛酶谱和双靶向活性的高效吡咯嘧啶抑制剂的设计 。 还 2012年elestvier有限公司保留所有权利。

著录项

  • 来源
  • 作者单位

    Trius Therapeutics 6310 Nancy Ridge Dr. San Diego CA 92121 United States;

    Trius Therapeutics 6310 Nancy Ridge Dr. San Diego CA 92121 United States;

    Trius Therapeutics 6310 Nancy Ridge Dr. San Diego CA 92121 United States;

    Trius Therapeutics 6310 Nancy Ridge Dr. San Diego CA 92121 United States;

    Trius Therapeutics 6310 Nancy Ridge Dr. San Diego CA 92121 United States;

    Trius Therapeutics 6310 Nancy Ridge Dr. San Diego CA 92121 United States;

    Trius Therapeutics 6310 Nancy Ridge Dr. San Diego CA 92121 United States;

    Trius Therapeutics 6310 Nancy Ridge Dr. San Diego CA 92121 United States;

    Trius Therapeutics 6310 Nancy Ridge Dr. San Diego CA 92121 United States;

    Trius Therapeutics 6310 Nancy Ridge Dr. San Diego CA 92121 United States;

    Trius Therapeutics 6310 Nancy Ridge Dr. San Diego CA 92121 United States;

    Trius Therapeutics 6310 Nancy Ridge Dr. San Diego CA 92121 United States;

    Lawrence Livermore National Laboratory Physical and Life Sciences Directorate Livermore CA 94550;

    Lawrence Livermore National Laboratory Physical and Life Sciences Directorate Livermore CA 94550;

    Lawrence Livermore National Laboratory Physical and Life Sciences Directorate Livermore CA 94550;

    Advanced Light Source Beamline 4.2.2 1 Cyclotron Rd. Berkeley CA 94720 United States;

    Trius Therapeutics 6310 Nancy Ridge Dr. San Diego CA 92121 United States;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

    Bacterial topoisomerases; GyrB; Inhibitor; ParE; Pyrrolopyrimidine;

    机译:细菌拓扑异构酶;GyrB;抑制剂;Pare;吡咯嘧啶;

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号